Pattern of relapse and progression after autologous SCT as upfront treatment for multiple myeloma

Bone Marrow Transplantation

Volumn 49, Issue 2, 2014, Pages 223-227

  Fernandez De Larrea C ^a   Jimenez R ^a   Rosinol L ^a   Gine E ^a   Tovar, N ^a   Cibeira, M T ^a   Fernandez Aviles F ^a   Martinez C ^a   Rovira, M ^a   Blade J ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Autologous transplantation; Multiple myeloma; Plasmacytoma; Progression; Relapse

Indexed keywords

ADULT; AGED; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PROGNOSIS; RECURRENCE; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS;

EID: 84893800663     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2013.150     Document Type: Article

References (23)

1. Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia 2009; 23: 3-9.
2. Bladé J, Rosiñ ol L, Cibeira MT, Rovira M, Carreras E. Hematopoietic stem cell transplantation for multiple myeloma beyond 2010. Blood 2010; 115: 3655-3663.
3. Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008; 111: 2516-2520.
4. Nadal E, Giné E, Bladé J, Esteve J, Rosiñ ol L, Fernández-Avilés F et al. High-dose therapy/autologous stem cell transplantation in patients with chemosensitive myeloma: predictors of complete remission. Bone Marrow Transplant 2004; 33: 61-64.
5. Dingli D, Pacheco JM, Dispenzieri A, Hayman SR, Kumar SK, Lacy MQ et al. Serum M-spike and transplant outcome in patients with multiple myeloma. Cancer Sci 2007; 98: 1035-1040.
6. Martinez-Lopez J, Blade J, Mateos MV, Grande C, Alegre A, Garcý́a-Laraña J et al. Long-term prognostic significance of response in multiple myeloma after stem cell transplantation. Blood 2011; 118: 529-534.
7. Alegre A, Granda A, Martý́nez-Chamorro C, Dý́az-Mediavilla J, Martý́nez R, Garcý́a- Laraña J et al. Different patterns of relapse after autologous peripheral blood stem cell transplantation inmultiple myeloma: clinical results of 280 cases from the Spanish Registry. Haematologica 2002; 87: 609-614.
8. Rajkumar SV, Harousseau JL, Durie B, Anderson KC, Dimopoulos M, Kyle R et al. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood 2011; 117: 4691-4695.
9. Bladé J, Fernández de Larrea C, Rosiñ ol L, Cibeira MT, Jiménez R, Powles R. Softtissue plasmacytomas in multiple myeloma: incidence, mechanisms of extramedullary spread, and treatment approach. J Clin Oncol 2011; 29: 3805-3812.
10. Bladé J, Samson D, Reece D, Apperley J, Bjö rkstrand B, Gahrton G et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT: European Group for Blood and Marrow Transplant. Br J Haematol 1998; 102: 1115-1123.
11. Alexanian R, Weber D, Delasalle K, Handy B, Champlin R, Giralt S. Clinical outcomes with intensive therapy for patients with primary resistant multiple myeloma. Bone Marrow Transplant 2004; 34: 229-234.
12. Alexanian R, Weber D, Giralt S, Dimopoulos M, Delasalle K, Smith T et al. Impact of complete remission with intensive therapy in patients with responsive multiple myeloma. Bone Marrow Transplant 2001; 27: 1037-1043.
13. Brenner H, Gondos A, Pulte D. Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood 2008; 111: 2521-2526.
14. Rosiñol L, Oriol A, Teruel AI, Hernández D, López-Jiménez J, de la Rubia J et al. Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study. Blood 2012; 120: 1589-1596.
15. Badros AZ. Lenalidomide in myeloma-a high-maintenance friend. N Engl J Med 2012; 366: 1836-1838.
16. Sanfructuoso C, Caballero MD, Garcia-Sanz R, Vidriales B, Vazquez L, San Miguel JF. Relapse of multiple myeloma in extramedullary sites after autologous bone marrow transplantation. Eur J Haematol 1996; 56: 181-183.
17. Dawson MA, Patil S, Spencer A. Extramedullary relapse of multiple myeloma associated with a shift in secretion from intact immunoglobulin to light chains. Haematologica 2007; 92: 143-144.
18. Zamarin D, Giralt S, Landau H, Lendvai N, Lesokhin A, Chung D et al. Patterns of relapse and progression in multiple myeloma patients after autoSCT: implications for patients monitoring after transplantation. Bone Marrow Transplant 2013; 48: 419-424.
19. Varettoni M, Corso A, Pica G, Mangiacavalli S, Pascutto C, Lazzarino M. Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients. Ann Oncol 2009; 21: 325-330.
20. Lenhoff S, Hjorth M, Turesson I, Westin J, Gimsing P, Wislö ff F et al. Intensive therapy for multiple myeloma in patients younger than 60 years. Long-term results focusing on the effect of the degree of response on survival and relapse pattern after transplantation. Haematologica 2006; 91: 1228-1233.
21. Zeiser R, Deschler B, Bertz H, Finke J, Engelhardt M. Extramedullary vs medullary relapse after autologous or allogeneic hematopoietic stem cell transplantation (HSCT) in multiple myeloma (MM) and its correlation to clinical outcome. Bone Marrow Transplant 2004; 34: 1057-1065.
22. Wu P, Davies F, Boyd K, Thomas K, Dines S, Saso RM et al. The impact of extramedullary disease at presentation in the outcome of myeloma. Leuk Lymphoma 2009; 50: 230-235.
23. Rajkumar SV, Merlini G, San Miguel JF. Haematological cancer: redefining myeloma. Nat Rev Clin Oncol 2012; 9: 494-496.